AIM: TMC114 is a new HIV protease inhibitor, used in combination with low-dose ritonavir (TMC114/r) as a pharmacokinetic enhancer. Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor. Both antiretrovirals show activity against wild-type and resistant HIV. An open-label crossover study was conducted in HIV - healthy volunteers to investigate the potential for a pharmacokinetic interaction between TMC114/r and tenofovir. METHODS: Two groups, each of six volunteers, were evaluated in two consecutive sessions. In session 1, volunteers received TMC114/r (300/100 mg bid) for 7 days, followed by a wash-out period of at least 6 days. In session 2, volunteers received TMC114/r (300/100 mg bid) plus TDF (300 mg qd). RESULTS: When TMC114/r and TDF were coadministered, tenofovir plasma concentrations (C(min) and C(max)), and area under the curve (AUC(24 h)) increased by 37%, 24% and 22%, respectively. When TDF and ritonavir were coadministered, TMC114 plasma C(min), C(max) and AUC(12 h) increased by 24%, 16% and 21%, respectively. There were no changes in the urinary excretion of unchanged tenofovir or TMC114 during coadministration. Administration of TMC114/r in HIV- healthy volunteers with or withoutTDF was well tolerated. CONCLUSIONS: The interaction between TMC114/r and tenofovir is not clinically relevant and no dose adjustments are required when these drugs are coadministered.
RCT Entities:
AIM: TMC114 is a new HIV protease inhibitor, used in combination with low-dose ritonavir (TMC114/r) as a pharmacokinetic enhancer. Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor. Both antiretrovirals show activity against wild-type and resistant HIV. An open-label crossover study was conducted in HIV - healthy volunteers to investigate the potential for a pharmacokinetic interaction between TMC114/r and tenofovir. METHODS: Two groups, each of six volunteers, were evaluated in two consecutive sessions. In session 1, volunteers received TMC114/r (300/100 mg bid) for 7 days, followed by a wash-out period of at least 6 days. In session 2, volunteers received TMC114/r (300/100 mg bid) plus TDF (300 mg qd). RESULTS: When TMC114/r and TDF were coadministered, tenofovir plasma concentrations (C(min) and C(max)), and area under the curve (AUC(24 h)) increased by 37%, 24% and 22%, respectively. When TDF and ritonavir were coadministered, TMC114 plasma C(min), C(max) and AUC(12 h) increased by 24%, 16% and 21%, respectively. There were no changes in the urinary excretion of unchanged tenofovir or TMC114 during coadministration. Administration of TMC114/r in HIV- healthy volunteers with or without TDF was well tolerated. CONCLUSIONS: The interaction between TMC114/r and tenofovir is not clinically relevant and no dose adjustments are required when these drugs are coadministered.
Authors: Marta Boffito; David Back; Meredith Stainsby-Tron; Andrew Hill; Giovanni Di Perri; Graeme Moyle; Mark Nelson; Jaqui Tomkins; Brian Gazzard; Anton Pozniak Journal: Br J Clin Pharmacol Date: 2005-01 Impact factor: 4.335
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Kathleen Squires; Anton L Pozniak; Gerald Pierone; Corklin R Steinhart; Daniel Berger; Nicholaos C Bellos; Stephen L Becker; Michael Wulfsohn; Michael D Miller; John J Toole; Dion F Coakley; Andrew Cheng Journal: Ann Intern Med Date: 2003-09-02 Impact factor: 25.391
Authors: Jennifer R King; Ram Yogev; Patrick Jean-Philippe; Bobbie Graham; Andrew Wiznia; Paula Britto; Vincent Carey; Rohan Hazra; Edward P Acosta Journal: Antimicrob Agents Chemother Date: 2011-06-13 Impact factor: 5.191
Authors: Jose R Castillo-Mancilla; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha Mawhinney; Peter L Anderson Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Babafemi O Taiwo; Ellen S Chan; Carl J Fichtenbaum; Heather Ribaudo; Athe Tsibris; Karin L Klingman; Joseph J Eron; Baiba Berzins; Kevin Robertson; Alan Landay; Igho Ofotokun; Todd Brown Journal: Clin Infect Dis Date: 2015-06-09 Impact factor: 9.079
Authors: James E Slaven; Brian S Decker; Angela D M Kashuba; Mohamed G Atta; Christina M Wyatt; Samir K Gupta Journal: J Acquir Immune Defic Syndr Date: 2016-09-01 Impact factor: 3.731